Adjuvant Interferon Treatment of Human Osteosarcoma

Recombinant Leukocyte Interferon Alpha-2A and Medroxyprogesterone in Advanced Renal Cell Carcinoma: A Randomized Trial

“…The drug is very useful in the treatment of some other disease, e.g. hairy-cell leukemia (13,14). Although it was impossible in this study to collect the information on adverse effects without the investigator knowing what treatment had been given, our impression is that the sensitivity and specificity in the registration is similar between the treatment groups.…”

Interferon-induced Remission in Aggressive Fibromatosis of the Lower Extremity

“…IFN has demonstrated effects against several types of solid tumors (10,11). The responses seen in individual cases can be impressive, although few patients respond.…”

Osteosarcoma and interferon

“…The treatment is, however, associated with severe morbidity, even mortality (Marroum et al 1977;Rosen et al 1979). At the Karolinska Hospital, a nomandomized, consecutive trial of adjuvant IFN treatment in osteosarcoma was initiated in I971 (Strander 1986). The 7 year survival rate, based on 83 patients treated between 1971 and 1986, was 44% (Bauer 1987).…”

“…Human natural IFN-a has been used clinically as adjuvans to surgical treatment of primary osteosarcoma (Strander 1986). The results of this trial is still inconclusive.…”

“…Assessment of the corresponding dose in humans is dependent on the conversion factor used for comparison. Hence, related to body surface area, 2 x 1 d IU in mice corresponds to 20 x1061U/m2 (Balkwill et al 1982); a dose which has been given to patients, for at least a limited period of time (Strander 1986). However, to achieve an equal serum concentration of IFN in humans, as was obtainedwith2x1051Uinmice,8 x1061U/kgwouldbe needed, i.e., 10 times higher than the maximum tolerated dose.…”